1. Home
  2. AR vs CYTK Comparison

AR vs CYTK Comparison

Compare AR & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Antero Resources Corporation

AR

Antero Resources Corporation

HOLD

Current Price

$32.16

Market Cap

9.9B

Sector

Energy

ML Signal

HOLD

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$64.35

Market Cap

8.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AR
CYTK
Founded
2002
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.9B
8.0B
IPO Year
2013
2004

Fundamental Metrics

Financial Performance
Metric
AR
CYTK
Price
$32.16
$64.35
Analyst Decision
Buy
Strong Buy
Analyst Count
18
16
Target Price
$44.35
$82.38
AVG Volume (30 Days)
5.2M
2.1M
Earning Date
02-11-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.87
N/A
Revenue
$5,007,754,000.00
$87,211,000.00
Revenue This Year
$24.23
$346.43
Revenue Next Year
$20.43
$57.69
P/E Ratio
$17.59
N/A
Revenue Growth
17.21
2609.26
52 Week Low
$29.10
$29.31
52 Week High
$44.02
$70.98

Technical Indicators

Market Signals
Indicator
AR
CYTK
Relative Strength Index (RSI) 37.80 53.27
Support Level $31.59 $58.85
Resistance Level $35.63 $64.43
Average True Range (ATR) 1.05 2.85
MACD -0.26 -0.02
Stochastic Oscillator 13.73 44.23

Price Performance

Historical Comparison
AR
CYTK

About AR Antero Resources Corporation

Antero Resources, based in Denver, explores for and produces natural gas and natural gas liquids in the United States and Canada. At the end of 2024, the company reported proven reserves of 17.9 trillion cubic feet of natural gas equivalent. Production averaged approximately 3,424 million cubic feet of equivalent a day in 2024 at a ratio of 35% liquids and 65% natural gas.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: